Projects per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 9 Finished
-
Comprehensive circulating nucleic acid analysis to identify biomarkers for immune checkpoint inhibitors (ICI) in metastatic castration-resistant prostate cancer (mCRPC)
Kwan, E. & Azad, A.
1/03/21 → 28/02/22
Project: Research
-
A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations
25/03/19 → 22/06/20
Project: Research
-
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
Hofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Buteau, J. P., Joshua, A. M., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., Ng, S., Francis, R. J., Gedye, C., Rutherford, N. K., Weickhardt, A., Scott, A. M., Lee, S. T., Kwan, E. M., Azad, A. A., Ramdave, S., & 12 others, Jan 2024, In: The Lancet Oncology. 25, 1, p. 99-107 9 p.Research output: Contribution to journal › Article › Research › peer-review
39 Citations (Scopus) -
Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial
Kwan, E. M., Spain, L., Anton, A., Gan, C. L., Garrett, L., Chang, D., Liow, E., Bennett, C., Zheng, T., Yu, J., Dai, C., Du, P., Jia, S., Fettke, H., Abou-Seif, C., Kothari, G., Shaw, M., Parente, P., Pezaro, C., Tran, B., & 2 others, Mar 2022, In: European Urology. 81, 3, p. 253-262 10 p.Research output: Contribution to journal › Article › Research › peer-review
38 Citations (Scopus) -
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer
Mak, B., Lin, H-M., Kwan, E. M., Fettke, H., Tran, B., Davis, I. D., Mahon, K., Stockler, M. R., Briscoe, K., Marx, G., Zhang, A., Crumbaker, M., Tan, W., Huynh, K., Meikle, T. G., Mellett, N. A., Hoy, A. J., Du, P., Yu, J., Jia, S., & 7 others, Dec 2022, In: BMC Medicine. 20, 1, 14 p., 112.Research output: Contribution to journal › Article › Research › peer-review
Open Access13 Citations (Scopus) -
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Hofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Joshua, A. M., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., Ng, S., Francis, R. J., Gedye, C., Rutherford, N. K., Weickhardt, A., Scott, A. M., Lee, S. T., Kwan, E. M., Azad, A. A., Ramdave, S., Redfern, A. D., & 13 others, 27 Feb 2021, In: The Lancet. 397, 10276, p. 797-804 8 p.Research output: Contribution to journal › Article › Research › peer-review
641 Citations (Scopus) -
68Ga-prostate-specific membrane antigen (PSMA) PET/CT as a clinical decision-making tool in biochemically recurrent prostate cancer
Davies, A., Foo, M., Gan, C. L., Kourambas, J., Redgrave, N., Donnellan, S., Appu, S., Williams, S., Coleman, A., Segelov, E., Bradley, J., Soo, G., Ramdave, S., Kwan, E. M. & Azad, A. A., Oct 2021, In: Asia-Pacific Journal of Clinical Oncology. 18, 5, p. e204-e210 6 p.Research output: Contribution to journal › Article › Research › peer-review